Skip to main content
Premium Trial:

Request an Annual Quote

Waters, Beckman Coulter at Opposite Ends of the BCW Index

Waters and Beckman Coulter both saw sharp movement in their stocks this past week, with Waters gaining 12.52 percent and Beckman declining 16.96 percent. The net effect on the BCW Index was minimal, with an overall drop limited to .37 percent.

Waters' shares gained momentum late last week after Merrill Lynch analyst Darryl Pardi upgraded the shares to a 'buy' and said he expected positive second-quarter results from the firm. He forecast 7 percent organic revenue growth for the quarter, which the firm surpassed by 1 percent (see related brief).

Shares in Beckman Coulter, on the other hand, dropped rapidly late last week after the firm announced a restructuring and lackluster second quarter (see related article). Its shares now sit at roughly the same place they were a year ago.

In comparison to the Index, the Dow Jones Industrial Average slipped .6 percent for the five-day trading period ended Tuesday, the Nasdaq gained .1 percent, and the Nasdaq Biotech Index posted a 2.8 percent gain.

BioCommerce Week’s Index to the
Diversified Molecular Biology Tools Companies
Company
Ticker
Current Price
(
July 26, 2005)
Last Price
(
July 19, 2005)
% Change
Agilent
A
25.98
25.95
0.12
Applied Biosystems
ABI
19.77
20.03
-1.30
Beckman
BEC
53.55
64.49
-16.96
Bio-Rad
BIO
59.2
58.46
1.27
Bruker
BRKR
4.08
4.17
-2.16
GE
GE
34.7
35.33
-1.78
Harvard Bio
HBIO
3.26
3.33
-2.10
Invitrogen
IVGN
86.5
85.12
1.62
Molecular Devices
MDCC
21.77
20.93
4.01
PerkinElmer
PKI
21.55
21.15
1.89
Qiagen
QGEN
13.08
12.83
1.95
Sigma
SIAL
57.69
57.93
-0.41
Strategene
STGN
8.2
8.36
-1.91
Thermo
TMO
29.7
27.71
7.18
Waters
WAT
44.5
39.55
12.52
Index Average  
32.24
32.36
-0.37
The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.